Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles for treatment of non-Hodgkin’s lymphoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles for treatment of non-Hodgkin’s lymphoma
Authors
Keywords
-
Journal
Science Advances
Volume 6, Issue 14, Pages eaaz9798
Publisher
American Association for the Advancement of Science (AAAS)
Online
2020-04-02
DOI
10.1126/sciadv.aaz9798
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Elimination Pathways of Nanoparticles
- (2019) Wilson Poon et al. ACS Nano
- Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma
- (2018) Kin Man Au et al. ACS Nano
- Antitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation
- (2018) Li Tian et al. DRUG DELIVERY
- Targeting the B cell receptor pathway in non-Hodgkin lymphoma
- (2018) Kelly Valla et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies
- (2018) Kerrie Faia et al. PLoS One
- A Revisit to the Pretargeting Concept—A Target Conversion
- (2018) Guozheng Liu Frontiers in Pharmacology
- Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
- (2017) Christophe Massard et al. EUROPEAN JOURNAL OF CANCER
- PLGA-PEG nanoparticles for targeted delivery of the mTOR/PI3kinase inhibitor dactolisib to inflamed endothelium
- (2017) Shima Gholizadeh et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
- (2017) Trisha M. Wise-Draper et al. Targeted Oncology
- Antibody-drug conjugates—an emerging class of cancer treatment
- (2016) Nikolaos Diamantis et al. BRITISH JOURNAL OF CANCER
- New insights into the pretargeting approach to image and treat tumours
- (2016) Malay Patra et al. CHEMICAL SOCIETY REVIEWS
- Diffuse large B-cell lymphoma: R-CHOP failure--what to do?
- (2016) B. Coiffier et al. Hematology-American Society of Hematology Education Program
- A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
- (2015) S. M. O'Brien et al. BLOOD
- Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma
- (2014) James S. Blachly et al. BRITISH JOURNAL OF HAEMATOLOGY
- Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
- (2014) Jason R. Westin Clinical Lymphoma Myeloma & Leukemia
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- B-cell receptor signaling as a driver of lymphoma development and evolution
- (2013) Carsten U. Niemann et al. SEMINARS IN CANCER BIOLOGY
- The B-cell receptor signaling pathway as a therapeutic target in CLL
- (2012) J. A. Woyach et al. BLOOD
- PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by Tumors
- (2011) Francesco Dituri et al. Clinical & Developmental Immunology
- Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
- (2011) M. Steiner et al. CLINICAL CANCER RESEARCH
- Antibody Conjugate Therapeutics: Challenges and Potential
- (2011) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer
- (2011) Jatin Roper et al. PLoS One
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
- (2010) B. Coiffier et al. BLOOD
- Bioorthogonal chemistry amplifies nanoparticle binding and enhances the sensitivity of cell detection
- (2010) Jered B. Haun et al. Nature Nanotechnology
- A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
- (2009) J. M. Pagel et al. BLOOD
- Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas
- (2008) Elias Drakos et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More